Last reviewed 2026-06-10 · How we verify

Advanced RET fusion-positive non-small cell lung cancer — Treatment Landscape & Competitive Intelligence

Advanced RET fusion-positive non-small cell lung cancer (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Advanced RET fusion-positive non-small cell lung cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Eli Lilly · 1 drug in Advanced RET fusion-positive non-small cell lung cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Advanced RET fusion-positive non-small cell lung cancer:

• Advanced RET fusion-positive non-small cell lung cancer treatment updates — RSS
• Advanced RET fusion-positive non-small cell lung cancer treatment updates — Atom
• Advanced RET fusion-positive non-small cell lung cancer treatment updates — JSON

Cite this brief

Drug Landscape (2026). Advanced RET fusion-positive non-small cell lung cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-ret-fusion-positive-non-small-cell-lung-cancer. Accessed 2026-06-10.

Related

• Advanced RET fusion-positive non-small cell lung cancer full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing